|
1
|
Sawyer EJ, Hanby AM, Poulsom R, Jeffery R,
Gillett CE, Ellis IO, Ellis P and Tomlinson IP: Beta-catenin
abnormalities and associated insulin-like growth factor
overexpression are important in phyllodes tumours and fibroadenomas
of the breast. J Pathol. 200:627–632. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Reik W, Dean W and Walter J: Epigenetic
reprogramming in mammalian development. Science. 293:1089–1093.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nordin M, Bergman D, Halje M, Engström W
and Ward A: Epigenetic regulation of the Igf2/H19 gene cluster.
Cell Prolif. 47:189–199. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Murrell A, Ito Y, Verde G, Huddleston J,
Woodfine K, Silengo MC, Spreafico F, Perotti D, De Crescenzo A,
Sparago A, et al: Distinct methylation changes at the IGF2-H19
locus in congenital growth disorders and cancer. PLoS One.
3:e18492008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shin JH, Li RW, Gao Y, Bickhart DM, Liu
GE, Li W, Wu S and Li CJ: Butyrate induced IGF2 activation
correlated with distinct chromatin signatures due to histone
modification. Gene Regul Syst Bio. 7:57–70. 2013.PubMed/NCBI
|
|
6
|
Murata A, Baba Y, Watanabe M, Shigaki H,
Miyake K, Ishimoto T, Iwatsuki M, Iwagami S, Yoshida N, Oki E, et
al: IGF2 DMR0 methylation, loss of imprinting, and patient
prognosis in esophageal squamous cell carcinoma. Ann Surg Oncol.
21:1166–1174. 2014. View Article : Google Scholar
|
|
7
|
Cheng YW, Idrees K, Shattock R, Khan SA,
Zeng Z, Brennan CW, Paty P and Barany F: Loss of imprinting and
marked gene elevation are 2 forms of aberrant IGF2 expression in
colorectal cancer. Int J Cancer. 127:568–577. 2010. View Article : Google Scholar
|
|
8
|
Giani C, Cullen KJ, Campani D and
Rasmussen A: IGF-II mRNA and protein are expressed in the stroma of
invasive breast cancers: An in situ hybridization and
immunohistochemistry study. Breast Cancer Res Treat. 41:43–50.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Steenman MJ, Rainier S, Dobry CJ, Grundy
P, Horon IL and Feinberg AP: Loss of imprinting of IGF2 is linked
to reduced expression and abnormal methylation of H19 in Wilms'
tumour. Nat Genet. 7:433–439. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ravenel JD, Broman KW, Perlman EJ, Niemitz
EL, Jayawardena TM, Bell DW, Haber DA, Uejima H and Feinberg AP:
Loss of imprinting of insulin-like growth factor-II (IGF2) gene in
distinguishing specific biologic subtypes of Wilms tumor. J Natl
Cancer Inst. 93:1698–1703. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cui H, Horon IL, Ohlsson R, Hamilton SR
and Feinberg AP: Loss of imprinting in normal tissue of colorectal
cancer patients with microsatellite instability. Nat Med.
4:1276–1280. 1998. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Takano Y, Shiota G and Kawasaki H:
Analysis of genomic imprinting of insulin-like growth factor 2 in
colorectal cancer. Oncology. 59:210–216. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang FR, He XB, Yang YH and Xie W: The
expression and imprinting status of insulin-like growth factor 2
gene in colorectal cancer. Zhonghua Yi Xue Yi Chuan Xue Za Zhi.
20:31–34. 2003.In Chinese. PubMed/NCBI
|
|
14
|
Jarrard DF, Bussemakers MJ, Bova GS and
Isaacs WB: Regional loss of imprinting of the insulin-like growth
factor II gene occurs in human prostate tissues. Clin Cancer Res.
1:1471–1478. 1995.PubMed/NCBI
|
|
15
|
Ito Y, Koessler T, Ibrahim AE, Rai S,
Vowler SL, Abu-Amero S, Silva AL, Maia AT, Huddleston JE,
Uribe-Lewis S, et al: Somatically acquired hypomethylation of IGF2
in breast and colorectal cancer. Hum Mol Genet. 17:2633–2643. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yun K, Soejima H, Merrie AE, McCall JL and
Reeve AE: Analysis of IGF2 gene imprinting in breast and colorectal
cancer by allele specific-PCR. J Pathol. 187:518–522. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yballe CM, Vu TH and Hoffman AR:
Imprinting and expression of insulin-like growth factor-II and H19
in normal breast tissue and breast tumor. J Clin Endocrinol Metab.
81:1607–1612. 1996.PubMed/NCBI
|
|
18
|
McCann AH, Miller N, O'Meara A, Pedersen
I, Keogh K, Gorey T and Dervan PA: Biallelic expression of the IGF2
gene in human breast disease. Hum Mol Genet. 5:1123–1127. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cui H, Onyango P, Brandenburg S, Wu Y,
Hsieh CL and Feinberg AP: Loss of imprinting in colorectal cancer
linked to hypomethylation of H19 and IGF2. Cancer Res.
62:6442–6446. 2002.PubMed/NCBI
|
|
20
|
Baba Y, Nosho K, Shima K, Huttenhower C,
Tanaka N, Hazra A, Giovannucci EL, Fuchs CS and Ogino S:
Hypomethylation of the IGF2 DMR in colorectal tumors, detected by
bisulfite pyrosequencing, is associated with poor prognosis.
Gastroenterology. 139:1855–1864. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shetty PJ, Movva S, Pasupuleti N,
Vedicherlla B, Vattam KK, Venkatasubramanian S, Ahuja YR and Hasan
Q: Regulation of IGF2 transcript and protein expression by altered
methylation in breast cancer. J Cancer Res Clin Oncol. 137:339–345.
2011. View Article : Google Scholar
|
|
22
|
Lim WK, Ong CK, Tan J, Thike AA, NG CC,
Rajasegaran V, Myint SS, Nagarajan S, Nasir ND, McPherson JR, et
al: Exome sequencing identifies highly recurrent MED12 somatic
mutations in breast fibroadenoma. Nat Genet. 46:877–880. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mishima C, Kagara N, Tanei T, Naoi Y,
Shimoda M, Shimomura A, shimazu K, Kim SJ and Noguchi S: Mutational
analysis of MED12 in fibroadenomas and phyllodes tumors of the
breast by means of targeted next-generation sequencing. Breast
Cancer Res Treat. 152:305–312. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cani AK, Hovelson DH, McDaniel AS, Sadis
S, Haller MJ, Yadati V, Amin AM, Bratley J, Bandla S, Williams PD,
et al: Next-gen sequencing exposes frequent MED12 mutations and
actionable therapeutic targets in phyllodes tumors. Mol Cancer Res.
13:613–619. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yoshida M, Sekine S, Ogawa R, Yoshida H,
Maeshima A, Kanai Y, Kinoshita T and Ochiai A: Frequent MED12
mutations in phyllodes tumours of the breast. Br J Cancer.
112:1703–1708. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Di Tommaso S, Tinelli A, Malvasi A and
Massari S: Missense mutations in exon 2 of the MED12 gene are
involved in IGF-2 overexpression in uterine leiomyoma. Mol Hum
Reprod. 20:1009–1015. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kaneda A, Wang CJ, Cheong R, Timp W,
Onyango P, Wen B, Iacobuzio-Donahue CA, Ohlsson R, Andraos R,
Pearson MA, et al: Enhanced sensitivity to IGF-II signaling links
loss of imprinting of IGF2 to increased cell proliferation and
tumor risk. Proc Natl Acad Sci USA. 104:20926–20931. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhao R, DeCoteau JF, Geyer CR, Gao M, Cui
H and Casson AG: Loss of imprinting of the insulin-like growth
factor II (IGF2) gene in esophageal normal and adenocarcinoma
tissues. Carcinogenesis. 30:2117–2122. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hubertus J, Lacher M, Rottenkolber M,
Müller-Höcker J, Berger M, Stehr M, von Schweinitz D and Kappler R:
Altered expression of imprinted genes in Wilms tumors. Oncol Rep.
25:817–823. 2011. View Article : Google Scholar
|
|
30
|
Yang B, Wagner J, Damaschke N, Yao T,
Wuerzberger-Davis SM, Lee MH, Svaren J, Miyamoto S and Jarrard DF:
A novel pathway links oxidative stress to loss of insulin growth
factor-2 (IGF2) imprinting through NF-κB activation. PLos One.
9:e880522014. View Article : Google Scholar
|
|
31
|
Cui H: Loss of imprinting of IGF2 as an
epigenetic marker for the risk of human cancer. Dis Markers.
23:105–112. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
van Roozendaal CE, Gillis AJ, Klijn JG,
van Ooijen B, Claassen CJ, Eggermont AM, Henzen-Logmans SC,
Oosterhuis JW, Foekens JA and Looijenga LH: Loss of imprinting of
IGF2 and not H19 in breast cancer, adjacent normal tissue and
derived fibroblast cultures. FEBS Lett. 437:107–111. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Woodson K, Flood A, Green L, Tangrea JA,
Hanson J, Cash B, Schatzkin A and Schoenfeld P: Loss of
insulin-like growth factor-II imprinting and the presence of
screen-detected colorectal adenomas in women. J Natl Cancer Inst.
96:407–410. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cui H, Cruz-Correa M, Giardiello FM,
Hutcheon DF, Kafonek DR, Brandenburg S, Wu Y, He X, Powe NR and
Feinberg AP: Loss of IGF2 imprinting: A potential marker of
colorectal cancer risk. Science. 299:1753–1755. 2003. View Article : Google Scholar : PubMed/NCBI
|
